nouscom, Autore presso Nouscom

Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial

D’Alise et al, 2026 Nature Medicine Published

Neoadjuvant personalized viral vaccine prevents tumor relapse in checkpoint-resistant murine melanoma model

Secli et al, Nous-PEV neoadjuvant, JITC Nov 2025

NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome

De Marco et al, Mol Cancer Ther, 2025

Tumor burden dictates the neoantigen features required to generate an effective cancer vaccine

Garzia I et al, Cancer Immunol Res. 2024

Göran Ando | MD

Göran has more than 35 years of leadership and management experience in the biotech and pharmaceutical industry, with Board positions at several global companies, including currently as Chairman [...]

Richard Davis | PHD

Rick joined Nouscom in September 2020 from Johnson and Johnson Innovation where he was the Global Oncology Venture and Transaction Lead. He was Chief Executive Officer of a European clinical [...]

Morena D’Alise | PhD

Morena has more than 15 years’ experience in Immunology. She joined Nouscom in 2016 as Senior group leader of the Immunology Department; she currently leads the Immunology team, drives company [...]

Sven Gogov | MD

Sven Gogov, MD, is an experienced global clinical development leader bringing over 15 years of pharmaceutical oncology experience and regulatory interactions to Nouscom. Sven joined Nouscom in [...]

Andrew Jefferson | MBA

Andrew is an Operating Partner at Versant Ventures and has been the Chief Operating Officer at Ridgeline Discovery since 2018. Ridgeline is Versant’s Discovery Engine which creates and operates [...]

Joachim (JR) Rothe | PhD

Joachim joined LSP in 2002 and is currently a Managing Partner and co-owner of the firm. His prime focus and responsibility within LSP is to invest in unlisted securities and the general [...]